Lexicon Pharmaceuticals, Inc. LXRX

I had this stored on my watchlist a year ago and was following it, but got distracted work and life. Look at it now. Got to go back to do the work on it again. Not sure if I’m too late to the party?‍♂️

LX9211 stall says a lot.

We have now a company very strong financially but the fact that there’s no partnership deal for moving into phase 3, and they are not taking it there alone, going into three large Pain conferences in March and being considerably behind their competitor tells me this is a completely busted play at this point.

I would have to think the lack of a partnership deal at this stage says no one feels like it’s worth pursuing. Otherwise everyone would be seeing how critical it is to launch a phase 3 in March 2026, here.

With a busted pain program, there is little real potential in future value. This was their potentially big asset.

Time to move on.

Anyone looking for a job in a phase 3 study

Apply directly on Lexicons website.

Associate Director, Clinical Operations
Medical Science Liaison (MSL) - Neurology
Supply Chain Planning Manager
Senior Clinical Scientist
Associate Director, Patient Marketing/Recruitment

Is Ray buying to pop the SP for the underwriters to get their profit for the cash raise? Seems like more of a news generator than anything else?

So earnings is March 5 th

I would have to think they are ready to announce the phase 3 plan for LX9211 then. If they were still in negotiations likely they would pushed the date out to allow for time to get the contract signed. Either that or they may not have any interest with potential partners therefore possibly start the trials on their own, which would be extremely risky.

Several major pain conferences in March, so ideal timing. Huge sense of urgency to get started as the are well behind their competitor in the space.

I feel the stock is either ready to takeoff or it’s gonna crash, I don’t see much of the keys for staying where it’s at now for long

At least someone is making money other than the shorts… is $1.52 the top?

The "Successful History" Verdict
There is a 100% success rate for full over-allotment exercises in Lexicon’s last two major offerings (2022 and 2023). This establishes a clear precedent: management successfully times catalysts or supports the stock price to ensure underwriters can exercise their options for a profit. For the current February 2026 raise, the underwriters are positioned to repeat this success if they exercise before the March 4 expiration

Wonder if this applies here, AI saying…

There is a common misconception that insiders cannot buy right before a PR. In reality, the legality hinges on Material Non-Public Information (MNPI).
The Disclosure Defense: If the company mentioned "multiple catalysts" in a public meeting a month ago, those catalysts are technically public knowledge. The specific timing of the PR is often at the discretion of the IR (Investor Relations) department.

I’d love to think tomorrow morning something happens to spike the price and help all of us Feb 20 th $1.50 call holders make a buck, lol

Ok, so why don’t he buy into the $1.30 offering? Confused. Why buy higher later?

March is a key month,

-AAPM PainConnect 2026: Scheduled for March 5–8, 2026, in Salt Lake City, UT. This is a primary venue for multidisciplinary pain care and innovation.
-ASIPP 28th Annual Meeting: Taking place March 19–21, 2026, in New Orleans, LA, focusing on interventional pain management.
-USASP Annual Scientific Meeting: Held March 23–26, 2026, in Philadelphia, PA. This meeting focuses on the latest scientific research in pain